$42.37
-1.01[-2.33%]
At close: Apr 19
$42.37
0[0.00%]
After Hours: 4:20PM EDT
Ultragenyx Pharmaceutical
(NASDAQ:RARE)Latest News for Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)
Ultragenyx Pharmaceutical Stock (NASDAQ: RARE)
Categories: All
Wednesday, April 17, 2024
Tuesday, April 16, 2024
Monday, April 15, 2024
- S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In MarchAvi Kapoor - 4 days ago
- Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day SessionAvi Kapoor - 4 days ago
- Crude Oil Down 1%; Charles Schwab Sales Top EstimatesAvi Kapoor - 4 days ago
- Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder StudyVandana Singh - 4 days ago
- Ultragenyx shares are trading lower after the company announced interim Phase 1/2 data in patients with Angelman Syndrome after treatment with GTX-102.Benzinga Newsdesk - 4 days ago
- Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market SessionAvi Kapoor - 4 days ago
- Ultragenyx Reveal New Data From Phase 1/2 Study Of GTX-102 For Treatment Of Angelman SyndromeBenzinga Newsdesk - 4 days ago
Friday, April 05, 2024
- Ultragenyx Pharmaceutical shares are trading higher after Cantor Fitzgerald reiterated its Overweight rating on the stock and maintained a $107 price target.Benzinga Newsdesk - Apr 5, 2024, 3:51PM
- Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 AnalystsBenzinga Insights - Apr 5, 2024, 12:00PM
- Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $107 Price TargetBenzinga Newsdesk - Apr 5, 2024, 9:21AM
Monday, March 18, 2024
Tuesday, February 27, 2024
Wednesday, February 21, 2024
Friday, February 16, 2024
Thursday, February 15, 2024
- Recap: Ultragenyx Pharmaceutical Q4 EarningsBenzinga Insights - Feb 15, 2024, 4:05PM
- Ultragenyx Reaffirms 2024 Total Revenue Outlook Of $500M-$530M, Est $504.31MBenzinga Newsdesk - Feb 15, 2024, 4:05PM
- Ultragenyx Pharmaceutical Q4 EPS $(1.52) Beats $(1.62) Estimate, Sales $127.39M Beat $119.38M EstimateBenzinga Newsdesk - Feb 15, 2024, 4:02PM
- The Latest Analyst Ratings For Ultragenyx PharmaceuticalBenzinga Insights - Feb 15, 2024, 11:00AM
- Cantor Fitzgerald Reiterates Overweight on Ultragenyx Pharmaceutical, Maintains $114 Price TargetBenzinga Newsdesk - Feb 15, 2024, 9:13AM
- Earnings Scheduled For February 15, 2024Benzinga Insights - Feb 15, 2024, 5:17AM
Wednesday, February 14, 2024
Tuesday, February 06, 2024
Monday, February 05, 2024
Tuesday, January 30, 2024
Thursday, January 25, 2024
Friday, January 19, 2024
Thursday, January 04, 2024
Wednesday, January 03, 2024
Monday, December 18, 2023
- Andelyn Biosciences Selected By Ultragenyx For Late-Stage Process Performance Qualification Manufacturing Of Novel Gene Therapy For Sanfilippo SyndromeHappy Mohamed - Dec 18, 2023, 9:38AM
- Ultragenyx Receives European Commission Decision For Evkeeza Expanded Indication In Children Aged 5 Years And Older With Homozygous Familial HypercholesterolemiaBenzinga Newsdesk - Dec 18, 2023, 8:08AM
Friday, December 08, 2023
Friday, November 03, 2023
Thursday, November 02, 2023
- Ultragenyx Reaffirms 2023 Expected Total Revenue Guidance Of $425M-$450MBenzinga Newsdesk - Nov 2, 2023, 4:42PM
- Ultragenyx Pharmaceutical Q3 GAAP EPS $(2.23) vs $(3.50) Last Year, Sales $98.05M Miss $109.63M EstimateBenzinga Newsdesk - Nov 2, 2023, 4:15PM
- Earnings Scheduled For November 2, 2023Benzinga Insights - Nov 2, 2023, 4:56AM
Wednesday, November 01, 2023
Wednesday, October 25, 2023
Tuesday, October 24, 2023
Monday, October 23, 2023
Thursday, October 19, 2023
- Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Oct 19, 2023, 1:52PM
- AT&T, Union Pacific, Las Vegas Sands And Other Big Stocks Moving Higher On ThursdayLisa Levin - Oct 19, 2023, 9:56AM
- Ultragenyx Pharmaceutical Prices Its $300M Underwritten Public Offering Of 8,333,334 Common Shares At $30/ShareBenzinga Newsdesk - Oct 19, 2023, 2:07AM